H2 receptor Inhibitors
1 drugsAbout H2 receptor
The histamine H2 receptor regulates gastric acid secretion in the stomach. Its physiological function makes it a relevant target for pharmaceutical intervention.
Currently, there is no genetic evidence data available linking the H2 receptor to specific diseases, limiting confidence in target validation.
One FDA-approved drug, Famotidine Preservative Free (Hikma), targets the H2 receptor. It is a small molecule approved in 2001 for 7 indications.
Top H2 receptor Drugs
Hikma is the only company with an approved drug targeting H2 receptor.
Low competition suggests an opportunity for new entrants, but also a potentially limited market.
H2 receptor Clinical Trials 88 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on H2 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 45 | 35 | 5 | 5 | 88% |
| Phase 2 | 21 | 10 | 5 | 6 | 67% |
| Phase 3 | 7 | 4 | 2 | 1 | 67% |
| Phase 4 | 15 | 8 | 3 | 4 | 73% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 56 (22 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on H2 receptor. A trial counts if an approved drug acting on H2 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.